<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03400735</url>
  </required_header>
  <id_info>
    <org_study_id>NEU-08.16</org_study_id>
    <nct_id>NCT03400735</nct_id>
  </id_info>
  <brief_title>Comparison of Cefdinir and Cefdinir/Clavulanic Acid Combination in Adults</brief_title>
  <official_title>Comparison of Cefdinir and Cefdinir/Clavulanic Acid Combination in Treatment of Acute Exacerbation of Chronic Bronchitis (AECB) and Community-acquired Pneumonia (CAP) in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neutec Ar-Ge San ve Tic A.Ş</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neutec Ar-Ge San ve Tic A.Ş</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is planned to compare the efficacy and safety of cefdinir and cefdinir/clavulanic acide
      treatments in acute exacerbation of chronic bronchitis (AECB) and community-acquired
      pneumoniae (CAP) patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">August 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The comparison of clinical success rates according to laboratory parameters</measure>
    <time_frame>7-10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The comparison of remission or relief of inflammation according to laboratory parameters</measure>
    <time_frame>7-10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The comparison of patient satisfaction according to satisfaction questionnaire</measure>
    <time_frame>7-10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The comparison of adverse events</measure>
    <time_frame>7-10 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Acute Exacerbation of Chronic Bronchitis</condition>
  <condition>Community-Acquired Pneumoniae</condition>
  <arm_group>
    <arm_group_label>Cefdinir/clavulanic acide 300/125 mg Film Coated Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cefdinir 300 mg Capsules</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Cefdinir/clavulanic acide 300/125 mg film-coated tablets</intervention_name>
    <description>Cefdinir is already an approved drug. In this study, developed cefdinir/clavulanic acide combination will be compared against to cefdinir alone.</description>
    <arm_group_label>Cefdinir 300 mg Capsules</arm_group_label>
    <other_name>Fullcef Plus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefdinir 300Mg Capsule</intervention_name>
    <description>Cefdinir is used as comparator</description>
    <arm_group_label>Cefdinir/clavulanic acide 300/125 mg Film Coated Tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The diagnosis of chronic bronchitis

          -  The diagnosis of community-acquired pneumoniae

          -  FEV1 value = 30-80%

          -  The diagnosis of mild-severe acute exacerbation of chronic bronchitis (AECB)

          -  Oxygen saturation &lt; 90%

        Exclusion Criteria:

          -  Pregnancy or breastfeeding

          -  Allergy against to penicillin or cephalosporins

          -  Renal impairment

          -  Active hepatic disease

          -  Antibiotic use except study drugs

          -  Immunosuppressive therapy before 6 months of study initiation

          -  Use of probenecid like drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Neutec R&amp;D</last_name>
    <phone>00902128505102</phone>
    <email>iremkaraman@neutecrdc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Erzincan University Mengücek Gazi Training and Research Hospital</name>
      <address>
        <city>Erzincan</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edhem Ünver, Assoc Prof</last_name>
    </contact>
    <investigator>
      <last_name>Edhem Ünver, Assoc Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yedikule Chest Diseases Training and Research Hospital</name>
      <address>
        <city>İstanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sedat Altın, Prof Dr</last_name>
    </contact>
    <investigator>
      <last_name>Sedat Altın, Prof Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gülşah Günlüoğlu, Assoc Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nurdan Kalkan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2016</study_first_submitted>
  <study_first_submitted_qc>January 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Bronchitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Cefdinir</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

